Production facilities and regulators in the medical industry know that drug testing needs to go beyond just effectiveness. To protect the health and well-being of customers in this space, businesses have had to withdraw pharmaceuticals from the market for toxicity concerns or unexpected drug interactions.
Medicine is a complicated field, and even a seemingly precise treatment can have unexpected side effects that make the product not worth the risk. ADME studies aim to integrate this testing directly into the discovery and development process. What is ADME, and how does it relate to similarly vital studies like toxicology, drug metabolism, and pharmacokinetics?
Before we dive into ADME, we need to cover the relationship between ADME and DMPK. These related studies in Drug Metabolism (DM) and Pharmacokinetics (PK) help medical research companies determine which drug candidates are worthy of further investigation.
Drug metabolism looks at how the body processes drugs into other compounds, primarily in the liver with drug-modifying enzymes (DME). These studies are particularly interested in whether the final products are potentially toxic.
What is a PK study? Pharmacokinetics measures how much of the drug is present throughout all parts of the body over time. PK gives deeper insight into how the pharmaceutical affects the patient and provides a benchmark to determine optimal dosage.
So what Is ADME in pharmacology? ADME is a medical acronym that covers several essential parameters drug companies analyze during pharmaceutical development. You might hear of it as ADMET, which adds another critical step, toxicology.
Because of how important ADME studies are to drug safety, these processes often occur early in the discovery process and are essential for regulatory approval. For instance, a drug candidate must pass these tests to continue on to later clinical programs.
ADME and pharmacokinetic studies will be necessary whenever a company wants to file for an Investigational New Drug (IND), New Drug Application (NDA), or a Biologics Licensing Application (BLA) from the FDA.
While FDA guidelines allow both in vitro and in vivo testing for ADME studies, only the latter method can evaluate pharmacokinetic properties. The FDA produces various guidelines to help the industry verify drug safety and efficacy. A few examples include:
Some testing conducted under the supervision of the Association of Assessment and Accreditation of Laboratory Animal Care (AAALAC) involves laboratory animals like rodents. If more detailed PK data is necessary, primates may be the test subjects for bioavailability, distribution, and exposure studies.
ADMET and PK studies play major roles in drug discovery and production, verifying exactly how the human body absorbs, processes, and excretes drug compounds. Therefore, companies must pay attention to these studies to choose suitable research candidates for testing and to verify compliance with FDA guidelines.
Whether you’re a team leader, you’re involved in preclinical studies, drug development process, or a clinical researcher, learning more about these vital studies is paramount to your success in future pharmaceutical development.
Are you looking to improve your knowledge of ADME, PK/TK, and drug metabolism? We recommend registering for:
Have questions about our courses? Get in touch with our team today.
Stay Informed
Since 2001 CfPIE has
Need help finding the right life sciences training courses? We can help you make the right choice based on your company's needs.
All Rights Reserved | CfPIE Inc. | Our courses and materials are copyrighted by CfPIE, Inc. and may not be used or reproduced without the written permission of CfPIE, Inc. management. | In partnership with CCC